ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

QTRX Quanterix Corporation

13.21
0.21 (1.62%)
29 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Quanterix Corporation NASDAQ:QTRX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.21 1.62% 13.21 12.91 13.54 13.26 12.65 13.00 667,894 01:00:00

Quanterix to Present at 45th Annual Goldman Sachs Global Healthcare Conference

05/06/2024 9:00pm

Business Wire


Quanterix (NASDAQ:QTRX)
Historical Stock Chart


From Jun 2024 to Jul 2024

Click Here for more Quanterix Charts.

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs 45th Annual Global Healthcare Conference. Toloue will speak alongside Chief Financial Officer Vandana Sriram in a fireside chat presentation on Wednesday, June 12, 2024, at 2:40 p.m. EST. The session will be made available to attendees and the general public via webcast.

Webcast Information

To access the live webcast of Quanterix’s fireside chat presentation at the conference, please visit this link.

Replays of the presentation will be available for a limited period following the conference. The presentation will also be made available through the Investor Relations section of the company’s website.

To learn more about Quanterix, visit www.quanterix.com/company. To learn more about Quanterix’s Simoa® technology, visit www.quanterix.com/simoa-technology.

About Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

Media Contact: PAN Communications Maya Nimnicht 510-334-6273 quanterix@pancomm.com

Investor Relations Contact: Quanterix Francis Pruell (508)-789-1725 ir@quanterix.com

1 Year Quanterix Chart

1 Year Quanterix Chart

1 Month Quanterix Chart

1 Month Quanterix Chart